RBC Raises Price Target on Jazz Pharmaceuticals to $305 From $296
RBC Capital Markets has increased its price target for Jazz Pharmaceuticals plc, maintaining an 'Outperform' rating on the stock.
Stocks · News reference
Jazz Pharmaceuticals' ZIIHERA Receives Regulatory Approvals for Biliary Tract Cancer
Jazz Pharmaceuticals' drug ZIIHERA (zanidatamab-hrii) has been granted accelerated approval in the U.S. and conditional marketing authorization in the European Union for the treatment of eligible biliary tract cancer (BTC) patients.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Jazz Pharmaceuticals plc (JAZZ)
Filed: 2026-11-02 AccNo: 0001232524-26-000056 Size: 932 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
Jazz Pharmaceuticals announced it will present clinical research data regarding its neuro-oncology portfolio at the 2026 Society for Neuro-Oncology (SNO) annual meeting.
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314
Jim Cramer Gives Green Light To This Health Care Stock
Cramer warns against Apple Hospitality if rates hit 6%, prefers Vylor over Corteva, backs Jazz, and notes SpaceX may bid for EchoStar.
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296